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LETTER TO THE EDITOR 
8-Methoxypsoralen Levels In Blood 
To the Editor: 
We read with interest the article by Chakrabarti et al [1) and have 
some remarks about the results and conclusions presented in this 
paper. 
At the end of the article the authors conclude. " Since our results 
appear to be higher than those reported elsewhere, we believe 
that the reverse-phase HPLC method is more sensitive . .. ". In 
our opinion, higher sensitivity does not explain high 8-meth-
oxypsoralen (8-MOP) concentrations. We also do not agree with 
the opinion that the reverse-phase high-performance liquid chro-
matography (HPLC) method is more sensitive than other analytic 
methods (e.g., the straight-phase HPLC method) that are in-
cluded in the reference list of Dr. Chakrabarti's article [1]. The 
difference between the 2 methods lies in the principle of sepa-
ration. Sensitivity, on the other hand, depends on the detection 
method used , which is UV -detection both with straight- and 
reverse-phase HPLC. Numerous reverse-phase HPLC methods 
fo r determination of 8-MOP in body fluids were recently re-
ported in the literature [2-4]. but none of them have been referred 
to in the article. 
We were astonished by the unusually high blood concentrations 
p resented in this paper-peak levels ranging from 130-3892 ng/ml. 
The phannacokinetic behavior of 8-MOP seems rather peculiar; 
e.g . , the 8-MOP concentration of 3892 ng/ ml after 2 h and of 
490 ng/ml after 3 h , indicating a half-life for elimination of about 
20 minutes! According to recent review articles [5 ,6] on clinical 
pharmacokinetics of8-MOP, the mean maximum serum or plasma 
concentrations are about 200 ng/ml (range 0-500 ng/ ml) and the 
half-life for elimination is about 1 h. Blood concentrations are 
67% of plasma or serum concentrations [7]. 
We also have some remarks about the assay of 8-MOP de-
scribed in this article. The exact composition of the mobile phase 
is not indicated. The sensitivity of the detector (0.1 A UFS) is 
ins ufficient for measurement of the 8-MOP standard curve 
(2 .0-20.0 ng) . The standard deviations of the peak heights of the 
s tandard curve are enormous (ranging from 17-23%) . The stan-
dard curve is not composed of spiked blood samples and covers 
the range from 2-20.0 ng per injection (equivalent to 20-100 
ng/ml blood), whereas most 8-MOP concentrations in patients 
are much higher than 100 ng/ml. Recovery studies have been 
done with 8-MOP concentrations ranging only from 5-30 ng/ ml 
blood. Our conclusion is that we cannot explain the unusually 
high 8-MOP concentrations with the incomplete assay data pre-
sented. 
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REPLY 
In response to the Letter to the Editor from Drs . Stolk, Siddiqui, 
and Cormane, we would like to clarify the issues that they have 
addressed in our paper (1 J. 
There seems to be a misunderstanding about our conclusions, 
as interpreted by them, in their opinion that "higher sensitivity 
does not explain higher 8-MOP concentrations." Our conclu-
sions clearly stated that "8-MOP is absorbed in the blood un-
evenly and varied from patient to patient. The fact that only 
50-60% of the patients with vitiligo responded to PUV A therapy 
may be related to the variation of absorption of the drug in in-
dividual patients. " We certainly maintain that some of our results 
are higher than reported by other investigators . Our vitiligo pa-
tient population consists primarily of nonwhite subjects. Other 
investigators primarily reported about white patients suffering 
from severe psoriasis [2-21]. Moreover, using the isotopic method, 
Murata and colleagues demonstrated that in rat blood trime-
thylpsoralen levels were in the order of 4000 ng/ ml [22] . Since 
the isotopic method is significantly more sensitive, our results 
may not be out of line [23-25]_ 
Since there are numerous factors that determine the extraction 
of the drug from the blood, sensitivity is only one of the factors. 
We believe that the reverse-phase high-performance liquid chro-
matography (HPLC) method is more sensitive compared with 
gas chromatographic, quantitative thin-layer chromatography 
(TLC) , 'normal-phase HPLC, and even earlier reverse-phase HPLC 
methods, since these methods could measure only 5-10 ng quan-
tities of the drug [26] . By using the reverse-phase HPLC, we can 
measure as little as 2 ng of 8-MOP with 80-90% confidence. 
Drs. de Wolff and Thomas reviewed many methods for psoralen 
assay. They mentioned that "Reverse-phase high performance 
liquid chromatography is the method of choice for determining 
methoxsalen concentrations in body fluids, but gas chromatog-
raphy with electron capture detection and thin-layer chromatog-
raphy with fluorescence detection also give favorable results." 
[26] Our results certainly are consistent with these remarks. . 
Dr. Stolk et al complained that we did not refer to certall1 
articles about reverse-phase HPLC. We would like to remind Dr. 
Stolk and colleagues that we never attempted to provide an alI-
inclusive citation; however, we did not intend to offend anyone. 
We also would like to draw the attention of Dr. Stolk et al the 
fact that we developed the original quantitative thin-layer chro-
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